Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Paratek Closes $60 Million Loan Using Zai Lab Royalties for Pay Off

publication date: Jan 5, 2021

Boston's Paratek Pharma closed a $60 million non-recourse loan with an affiliate of R-Bridge Healthcare that will be paid off by royalties from Paratek's China omadacycline out-licensing agreement with Zai Lab. In May 2020, Zai filed an NDA for Paratek's omadacycline, an antibiotic, that was accepted by China's NMPA for priority review. Omadacycline was tested as a treatment for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. R-Bridge is part of China's CBC Group (formerly C-Bridge Capital). More details....

Stock Symbols: (NSDQ: PRTK) (NSDQ: ZLAB; HK: 9688)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021